Ikarian Capital LLC Sells 245,146 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS)

Ikarian Capital LLC cut its holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS) by 70.8% during the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 101,325 shares of the company’s stock after selling 245,146 shares during the quarter. Ikarian Capital LLC’s holdings in iTeos Therapeutics were worth $1,382,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of ITOS. Acadian Asset Management LLC acquired a new stake in iTeos Therapeutics in the first quarter valued at about $3,337,000. Kennedy Capital Management LLC acquired a new stake in iTeos Therapeutics in the first quarter valued at about $1,988,000. Vontobel Holding Ltd. boosted its stake in iTeos Therapeutics by 41.9% in the fourth quarter. Vontobel Holding Ltd. now owns 220,056 shares of the company’s stock valued at $2,410,000 after buying an additional 64,981 shares in the last quarter. Sectoral Asset Management Inc. boosted its stake in iTeos Therapeutics by 41.9% in the fourth quarter. Sectoral Asset Management Inc. now owns 220,056 shares of the company’s stock valued at $2,410,000 after buying an additional 64,981 shares in the last quarter. Finally, Jump Financial LLC acquired a new stake in iTeos Therapeutics in the fourth quarter valued at about $636,000. 97.16% of the stock is owned by institutional investors and hedge funds.

iTeos Therapeutics Stock Down 0.7 %

Shares of ITOS stock traded down $0.13 during mid-day trading on Thursday, reaching $17.46. 186,717 shares of the stock traded hands, compared to its average volume of 348,146. The stock’s fifty day simple moving average is $16.13 and its two-hundred day simple moving average is $13.34. iTeos Therapeutics, Inc. has a 1-year low of $8.20 and a 1-year high of $18.75. The company has a market cap of $630.66 million, a price-to-earnings ratio of -4.62 and a beta of 1.40.

iTeos Therapeutics (NASDAQ:ITOS) last announced its quarterly earnings results on Friday, May 10th. The company reported ($1.07) EPS for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.05). On average, equities research analysts anticipate that iTeos Therapeutics, Inc. will post -4.57 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on ITOS shares. Wedbush reaffirmed an “outperform” rating and issued a $21.00 price objective on shares of iTeos Therapeutics in a research note on Monday, June 17th. HC Wainwright lifted their price target on iTeos Therapeutics from $44.00 to $46.00 and gave the company a “buy” rating in a research note on Monday, May 13th.

iTeos Therapeutics Profile

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.